ApicHope Pharmaceutical Group Co., Ltd. (SHE:300723)
China
· Delayed Price · Currency is CNY 35.90
+0.44 (1.24%)
May 13, 2025, 2:45 PM CST
SHE:300723 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,174 | 1,419 | 2,489 | 2,275 | 2,195 | 1,675 | Upgrade
|
| Other Revenue | 30.76 | 30.76 | 14.04 | 4.95 | 3.82 | 0.21 | Upgrade
|
| Revenue | 1,204 | 1,450 | 2,503 | 2,280 | 2,199 | 1,675 | Upgrade
|
| Revenue Growth (YoY) | -50.03% | -42.07% | 9.79% | 3.68% | 31.26% | 2.32% | Upgrade
|
| Cost of Revenue | 572.13 | 576.21 | 481.98 | 300.2 | 321.98 | 297.66 | Upgrade
|
| Gross Profit | 632.19 | 874.02 | 2,021 | 1,980 | 1,877 | 1,378 | Upgrade
|
| Selling, General & Admin | 741.78 | 829.71 | 1,414 | 1,464 | 1,447 | 1,034 | Upgrade
|
| Research & Development | 286.2 | 312.09 | 301.37 | 189.78 | 142.32 | 135.34 | Upgrade
|
| Other Operating Expenses | 25.87 | 24.35 | 72.86 | 30.39 | 30.44 | 21.5 | Upgrade
|
| Operating Expenses | 1,055 | 1,167 | 1,792 | 1,685 | 1,621 | 1,193 | Upgrade
|
| Operating Income | -422.97 | -293.44 | 229.35 | 294.58 | 256.25 | 184.38 | Upgrade
|
| Interest Expense | -39.38 | -35.11 | -37.65 | -28.96 | -38.51 | -11.75 | Upgrade
|
| Interest & Investment Income | 29.55 | 3.72 | 11.71 | 8.46 | 28.96 | 15.08 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.31 | 1.31 | -5.51 | 0.1 | -0.47 | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.42 | -3.28 | -1.27 | -1.78 | -6.41 | -0.17 | Upgrade
|
| EBT Excluding Unusual Items | -431.91 | -326.79 | 196.63 | 272.4 | 239.82 | 187.44 | Upgrade
|
| Impairment of Goodwill | -11.03 | -11.03 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -40.11 | -40.11 | -24.64 | -28.31 | 23.96 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.26 | 1.27 | 0.12 | 0.19 | -0.07 | 0.03 | Upgrade
|
| Asset Writedown | -15.85 | -15.85 | -1.02 | -0.45 | -1.34 | -0.06 | Upgrade
|
| Other Unusual Items | -199.65 | -253.2 | 73.09 | 82.59 | 100.4 | 85.88 | Upgrade
|
| Pretax Income | -697.28 | -645.71 | 244.19 | 326.41 | 362.77 | 273.3 | Upgrade
|
| Income Tax Expense | -88.53 | -79 | 92.39 | 64.32 | 69.36 | 49.66 | Upgrade
|
| Earnings From Continuing Operations | -608.75 | -566.71 | 151.8 | 262.1 | 293.41 | 223.64 | Upgrade
|
| Minority Interest in Earnings | 24.79 | 26.67 | 32.82 | 28.59 | 13.5 | 1.97 | Upgrade
|
| Net Income | -583.96 | -540.04 | 184.61 | 290.68 | 306.92 | 225.61 | Upgrade
|
| Net Income to Common | -583.96 | -540.04 | 184.61 | 290.68 | 306.92 | 225.61 | Upgrade
|
| Net Income Growth | - | - | -36.49% | -5.29% | 36.04% | 57.02% | Upgrade
|
| Shares Outstanding (Basic) | 452 | 452 | 452 | 429 | 422 | 434 | Upgrade
|
| Shares Outstanding (Diluted) | 452 | 452 | 452 | 433 | 424 | 434 | Upgrade
|
| Shares Change (YoY) | 0.13% | -0.00% | 4.43% | 1.94% | -2.20% | 0.64% | Upgrade
|
| EPS (Basic) | -1.29 | -1.20 | 0.41 | 0.68 | 0.73 | 0.52 | Upgrade
|
| EPS (Diluted) | -1.29 | -1.20 | 0.41 | 0.67 | 0.72 | 0.52 | Upgrade
|
| EPS Growth | - | - | -39.18% | -7.09% | 39.10% | 56.02% | Upgrade
|
| Free Cash Flow | -818.67 | -870.18 | 123.59 | -130.25 | -123.13 | -38.93 | Upgrade
|
| Free Cash Flow Per Share | -1.81 | -1.93 | 0.27 | -0.30 | -0.29 | -0.09 | Upgrade
|
| Dividend Per Share | - | - | 0.210 | 0.133 | 0.133 | 0.093 | Upgrade
|
| Dividend Growth | - | - | 57.54% | - | 43.95% | 24.97% | Upgrade
|
| Gross Margin | 52.49% | 60.27% | 80.75% | 86.83% | 85.36% | 82.23% | Upgrade
|
| Operating Margin | -35.12% | -20.23% | 9.16% | 12.92% | 11.65% | 11.00% | Upgrade
|
| Profit Margin | -48.49% | -37.24% | 7.37% | 12.75% | 13.96% | 13.47% | Upgrade
|
| Free Cash Flow Margin | -67.98% | -60.00% | 4.94% | -5.71% | -5.60% | -2.32% | Upgrade
|
| EBITDA | -240.07 | -115.53 | 387.34 | 366.46 | 305.79 | 225.05 | Upgrade
|
| EBITDA Margin | -19.93% | -7.97% | 15.47% | 16.07% | 13.91% | 13.43% | Upgrade
|
| D&A For EBITDA | 182.89 | 177.91 | 157.99 | 71.89 | 49.54 | 40.68 | Upgrade
|
| EBIT | -422.97 | -293.44 | 229.35 | 294.58 | 256.25 | 184.38 | Upgrade
|
| EBIT Margin | -35.12% | -20.23% | 9.16% | 12.92% | 11.65% | 11.00% | Upgrade
|
| Effective Tax Rate | - | - | 37.84% | 19.70% | 19.12% | 18.17% | Upgrade
|
| Revenue as Reported | 1,204 | 1,450 | 2,503 | 2,280 | 2,199 | 1,675 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.